UBS Group »

Vyne Therapeutics shares owned by UBS Group

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by UBS Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $2.1k 846 2.50
2023-09-30 $749 184 4.07
2023-06-30 $4.4k 1.1k 4.07
2023-03-31 $1.1k 365 3.07

More positions owned by UBS Group

Microsoft Corporation (MSFT)
Apple Call Option (AAPL)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
NVIDIA Corporation (NVDA)
Ubs Group SHS (UBS)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr 20 Yr Tr Bd Etf (TLT)
Union Pacific Corporation (UNP)
Alphabet Cap Stk Cl C Put Option (GOOG)
Meta Platforms Cl A (META)

View all positions for UBS Group

Top funds holding Vyne Therapeutics

Cormorant Asset Management
Eventide Asset Management
Citadel Advisors
Soleus Capital Management
DSC Advisors
Palo Alto Investors
AlphaCentric Advisors
Exome Asset Management
Fred Alger Management
Vanguard Group
Millennium Management
Hrt Financial
Us Bancorp
Bank of America Corporation
Royal Bank of Canada

View all funds holding Vyne Therapeutics